EMEA-000380-PIP10-23 - paediatric investigation plan

secukinumab

Key facts

• Invented name:
  Cosentyx
• Active substance:
  secukinumab
• Therapeutic area:
  Immunology-Rheumatology-Transplantation
• Decision number:
  P/0201/2023
• PIP number:
  EMEA-000380-PIP10-23
• Pharmaceutical form(s):
  All pharmaceutical forms
• Condition(s) / indication(s):
  Treatment of polymyalgia rheumatica
• Route(s) of administration:
  All routes of administration
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  13/06/2023
• Compliance check done:
  Nie

Decision

P/0201/2023 : EMA decision of 13 June 2023 on the granting of a product specific waiver for secukinumab (Cosentyx), (EMEA-000380-PIP10-23)

Reference Number: EMA/241874/2023